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The aim of the clinical toxicological laboratory is to identify
substances which might harm the patient. This may be the elucida-
tion of an acute intoxication due to the intake of an overdose, the
clarification of a chronic toxic process or the verification of an
intake of substances which should not be taken by a patient.
Patients with recurring hypoglycaemia either have a deregula-
tion in glucose metabolism, a tumour in the pancreas or take anti-
diabetic drugs without having diabetes.
A.M. was admitted to the hospital with recurring hypoglycae-
mic events in order to clarify the symptoms. One of the first tests
performed is the fasting test, which does not allow the patient to
eat during max. 72 h in order to evaluate the regulation of glucose
metabolism. Regularly blood samples are taken to measure glucose
concentration, different hormone levels, and in order to exclude the
intake of antidiabetic drugs, a screening for these drugs should be
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HPLC-MS chromatograms showing the separation of the seven sulfonylurea
drugs available in Switzerland
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offered. Thus A.M. had to fast and at the beginning and the end of
the fasting test a blood sample was taken for the quantification of
the antidiabetic drugs.
The laboratory therefore needs a fast, specific and sensitive
analytical method for the quantitative determination of sulfonyl-
urea drugs.
Due to their chemical structure the commonly used GC-MS
methods used in clinical toxicological laboratories cannot be ap-
plied for the quantification of sulfonylurea drugs. Consequently,
an HPLC-MS method has been developed using atmospheric pres-
sure chemical ionisation and a chromatographic separation on a
C18 column with ammonium carbonate buffer and acetonitrile as
mobile phase. The plasma samples are extracted using solid-phase
extraction. The subsequent HPLC-MS separation can identify and
quantify the drugs in question due to their retention times and mo-
lecular masses.
In the serum of A.M. the antidiabetic drug glibenclamide was
detected, which was intended for use by her husband only. She has
no pancreatic tumour.
Applying this method on samples from patients with recur-
ring hypoglycaemia helps to reduce costs for invasive diagnostic
tools, which are necessary to look for tumours in the pancreas.
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